Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy.

ABSTRACT: Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression profiling. Circulating markers represent opportunities to assess baseline and dynamic changes in immune cell frequency and cytokine levels while on treatment. We conducted an exploratory prospective correlative study of 33 patients with metastatic clear cell renal cell carcinoma undergoing treatment with ICIs and correlated changes in circulating immune cell subsets and cytokines with clinical responses to treatment. Cell frequencies and cytokine levels were compared between responders and nonresponders using unpaired parametric t tests,

SUBMITTER: Hwang J 

PROVIDER: S-EPMC11949027 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature